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Biliary atresia is a devastating cholestatic liver disease of
children of unknown etiology. Research pertaining to the
immunopathogenesis of biliary atresia should focus on
unique aspects of neonatal immunity that promote aggres-
sive and ongoing inﬂammation and ﬁbrosis early in life.
Biliary atresia (BA) is the most frequent identiﬁable cause
of neonatal cholestasis, and the majority of patients will
need liver transplantation for survival. Despite surgical
intervention with the Kasai portoenterostomy, signiﬁcant
ﬁbrosis and cirrhosis develop early in life. An increased
understanding of what causes this inﬂammatory ﬁbrosing
cholangiopathy will lead to therapies aimed at protecting
the intrahepatic biliary system from immune-mediated
damage. This review focuses on studies pertaining to the
role of the adaptive immune response in bile duct injury in
BA, including cellular and humoral immunity. The
neonatal presentation of BA prompts the question of what
potential modiﬁcations of unique aspects of the neonatal
immune system set the stage for the progressive biliary
disease. This review also discusses the characteristics of
neonatal immune response and the theories on how
alterations of this response could contribute to the path-
ogenesis of BA. These include aberrant type 1 helper T-cell
(TH1) and TH17 responses, deﬁciencies in regulatory T
cells, activation of humoral immunity, and autoimmunity.
To advance our understanding of the etiology of BA, future
studies should focus on the unique aspects of the neonatal
immune system that have gone awry. (Cell Mol Gastro-
enterol Hepatol 2015;1:267–274; http://dx.doi.org/
10.1016/j.jcmgh.2015.04.001)
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http://dx.doi.org/10.1016/j.jcmgh.2015.04.001Bcause of neonatal cholestasis, occurring in approxi-
mately 1 out of 12,000 live births in the United States and
accounting for an estimated350newcases annually. It ismost
common in Taiwan (w1:5,600 live births) and occurs more
frequently in females, Asians, and African Americans.1 There
are three types of BA: isolated BA (84% of cases), BA with at
least one malformation but without laterality defects (6%;
cardiovascular, gastrointestinal, or genitourinary defects),and BA splenic malformation, a syndrome associated with
laterality defects and polysplenia or asplenia (4% to 10%).2
In isolated BA, meconium and initial stools are normal in
color, suggesting early patency of the ducts. However, within
theﬁrst 3months of age, the extrahepatic biliary tree becomes
obstructed, and the pathology is consistent with an inﬂam-
matory ﬁbrosing cholangiopathy. At diagnosis, the extrahe-
patic biliary remnant is removed, and a Kasai
portoenterostomy is performed in an attempt to reestablish
bile ﬂow. This results in initial restoration of bile ﬂow in up to
two-thirds of patients if performed within 60 days of life.
Even with surgical intervention, signiﬁcant ﬁbrosis and
cirrhosis develops early in life, and the majority of patients
will need liver transplant for survival. Analysis of liver tissue
from BA patients >4 years old after a Kasai portoenter-
ostomy revealed that, despite resolution of cholestasis in
83% of patients, 100% of patients had ﬁbrosis (Metavir stage
>2) or cirrhosis.3 On average, 20% of children with BA will
enter adulthood with their native liver, and the vast majority
of those patientswill have evidence of chronic liver disease or
cirrhosis.4 An increased understanding of what causes the
inﬂammatory sclerosing cholangiopathy of BA could lead to
therapies aimed at protecting the intrahepatic biliary system
from inﬂammatory-mediated damage and ﬁbrosis.
The etiology of BA is unknown, and theories of its
pathogenesis include perinatal virus infection targeting
cholangiocytes, chronic inﬂammatory or autoimmune-
mediated bile duct injury, and abnormalities in bile duct
development.5 A recent retrospective study of neonatal
direct bilirubin levels obtained at 24 to 48 hours of life has
shed light on the timing of the initial bile duct injury in BA.6
In that study, neonatal direct bilirubin levels were obtained
for all newborns in a single hospital between 2007 and
2010, and the infants who later developed isolated BA were
compared with newborns from the same period who did not
have BA. The BA newborns had mean direct bilirubin levels
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± 0.43 vs. 0.19 ± 0.075 mg/dL), suggesting that the bile duct
damage began in utero. A leading hypothesis in the patho-
genesis of isolated BA is that the cholangiocyte injury is
initiated by a virus infection followed by an exaggerated
autoinﬂammatory or autoimmune response that targets bile
duct epithelia, resulting in progressive bile duct damage and
obliteration.7 In this theory, the virus infection is short lived,
but the cholangiocytes within the entire biliary tree may
continue to be damaged by aberrant autoimmune mecha-
nisms. Cholangiocyte proteins may be seen as foreign
because of alterations from the virus or exposure of previ-
ously sequestered antigens. Alternatively, the virus and
epithelial proteins could have a high degree of sequence
homology leading to antiviral and autoimmune responses
that overlap, an autoimmune mechanism known as molec-
ular mimicry.
This review will focus on studies pertaining to the role of
the adaptive immune response in bile duct injury in BA,
including cellular (T cell) and humoral (B cell) immunity.
The signiﬁcance of T cells versus B cells in disease pathol-
ogy cannot be easily separated, as the two arms of adaptive
immunity are intertwined. T cells provide “help” for B-cell
immunoglobulin isotype switching and antibody production.
B cells function as antigen-presenting cells or producers of
cytokines for T-cell activation. The neonatal presentation of
BA prompts the question of what potential modiﬁcations of
known unique aspects of the neonatal immune system set
the stage for the progressive biliary disease. In this review I
discuss the characteristics of the neonatal immune response
and the theories of how alterations of this response could
contribute to the pathogenesis of BA. Innate immune re-
sponses in the infant with BA also contribute to bile duct




Adaptive cellular immunity involves the interaction of
antigen-presenting cells with T cells, resulting in activation
of T cells with the production of cytokines. Adaptive im-
mune responses are triggered by repeat exposure to both
pathogen and non-microbial antigens, resulting in highly
speciﬁc memory T-cell activation. Aspects of adaptive
cellular immunity that characterize the neonate include
decreased frequencies and function of dendritic cells (anti-
gen-presenting cells) compared with adults and T-cell
responses that are skewed to a type 2 helper T cell (TH2)
proﬁle, with the production of interleukin 4 (IL-4), IL-5, and
IL-13. It is becoming clear that neonates are also capable of
generating adult-like TH1 responses (IL-2, interferon-g
[IFN-g]) when the conditions for antigenic priming are
optimized. Over 30 years ago, Hoffman et al described T-
cell responses in neonatal mice and found that infection
with a high dose of a murine leukemic virus (>1,000
plaque-forming units) led to nonprotective TH2 responses
and disease.10 In stark contrast, a low exposure of virus
(0.3 plaque-forming units) to the neonate induced avirus-speciﬁc TH1 response with clearance of virus.
11 These
studies have led to the hypothesis that BA pathogenesis
could be related to low-dose neonatal virus infection with
proinﬂammatory TH1 immune responses. Multiple studies
have since shown that neonates are able to mount fully
mature TH1 responses under certain circumstances, which
increases costimulatory signals on antigen-presenting
cells.12–14 It can therefore be theorized that an abnormal
skewing of the T-cell response in the neonate from the
default TH2 response to the inﬂammatory TH1 response
could be an early event that promotes ongoing T-cell-
mediated bile duct injury in BA.
The predominant cellular immune response in BA at
diagnosis encompasses activated CD4þ and CD8þ T cells
within portal tracts that produce TH1 cytokines (IL-2, IFN-g,
tumor necrosis factor a [TNF-a]) and macrophages
secreting TNF-a.15–17 These lymphocytes have been found
invading between bile duct epithelia, resulting in degener-
ation of intrahepatic bile ducts.18 With the aim of under-
standing whether the inﬂammation is nonspeciﬁc
(bystander activation) versus antigen speciﬁc with expan-
sion of clones of T cells, T-cell receptor characterization was
performed. Analysis of the T-cell receptor variable region of
the b-chain (Vb) within BA liver and extrahepatic bile duct
remnants revealed that the T cells were indeed oligoclonal
in nature with a limited T-cell receptor Vb repertoire, sug-
gesting antigen-speciﬁc activation. The exact antigen(s)
stimulating the clonal expansions remains a mystery that if
solved will provide a wealth of information on the processes
of T-cell-mediated bile duct injury in BA.19TH1 Cellular Immunity
To perform mechanistic studies of immune-mediated
hypotheses, the Rhesus group A rotavirus (RRV)-induced
mouse model of BA (murine BA) has been employed by
many investigators. This model mimics many aspects of the
human disease, including bile duct epithelial apoptosis,
portal inﬂammation, intrahepatic bile ductule proliferation,
and extrahepatic biliary obstruction. The main limitation of
the mouse model is that the extrahepatic biliary ﬁbrosis is
minimal compared with humans and the biliary obstruction
is mainly due to inﬂammation and edema.
Many investigators view the ﬁndings in the mouse model
as representative of the early events in human BA. In mu-
rine BA the virus is cleared within the ﬁrst 2 weeks of life, a
time point when extrahepatic biliary obstruction is com-
plete. The CD4þ TH1 cellular inﬂammatory environment
found in murine BA recapitulates the human disease, and
the progressive inﬂammatory destruction and obliteration
of the bile ducts leads to death by 3 weeks of age.20,21 In
support of a TH1 cytokine environment in BA mice, many
investigators have described increased levels of chemokines
that promote TH1 cellular differentiation [chemokine (C-C
motif) ligand 2, chemokine (C-C motif) ligand 5, C-X-C motif
chemokine 10].22,23 IFN-g is a necessary cytokine in the
pathogenesis of murine BA, as RRV-infected IFN-g knockout
mice are protected from developing biliary obstruction and
have a dramatic increase in survival.24
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with increased survival, and the CD8þ T cells from BA mice
were found to be directly cytotoxic to cholangiocytes
in vitro.25 A recent study by Zheng et al26 further analyzed
the CD8þ T-cell response in murine BA. Multiple RRV
nonstructural protein 4 (NSP4) constructs were created to
assess which viral epitope was responsible for CD8þ T-cell
activation. A computer based program was utilized that
predicted which NSP4 viral epitopes would most likely
interact with CD8þ T cells. A fusion protein composed of
glutathione S-transferase and NSP4 (GST-NSP4), as well as
NSP4144–152 and NSP157–170 epitopes, were all recognized by
CD8þ T cells and induced CD8þ T-cell IFN-g production,
similar to that found with RRV stimulation. Injection of
neonatal mice with GST-NSP4, and not other viral con-
structs, led to biliary obstruction similar to RRV-infected
mouse pups. Liver CD8þ T cells from NSP4144–152,
NSP157–170, and GST-NSP4 injected mice that were cultured
with bile duct epithelial cells led to direct epithelial cyto-
toxicity. The fact that the viral epitope-speciﬁc liver CD8þ T
cells also recognized proteins within bile duct epithelia and
elicited cellular damage suggests molecular mimicry as a
potential mechanism of autoimmune activation. The re-
searchers concluded that NSP4 is a pathogenic immunogen
that initiates the inﬂammatory response, resulting in bile
duct epithelial injury in murine BA. Collectively, these
studies suggest that CD4þ TH1 cells may activate CD8
þ
cytotoxic T cells and that both subsets contribute to the
biliary injury and obstruction in BA.
The murine BA model has been used to understand the
role of cellular autoimmunity in bile duct injury. Periductal
inﬂammation involves an inﬂux of bile duct epithelial-
speciﬁc IFN-g–producing T cells.27 This was determined
based on liver memory T-cell activation when cells were
cultured with a bile duct epithelial homogenate protein
source. In vitro analysis revealed that inhibition of CD4þ T
cells, but not CD8þ T cells, was associated with loss of IFN-g
production, identifying the CD4þ T cell as the key cell type
associated with bile duct-speciﬁc autoimmune activation.
Adoptive transfer of the liver T cells from BA mice into
immunodeﬁcient recipient mice resulted in bile duct-
targeted inﬂammation.25,27 Similar to human BA, the exact
identity of the bile duct antigens that are being targeted has
not been elucidated.TH2 Cellular Immunity
There is a rare subgroup of BA patients who present
with a biliary cystic form of atresia. In this anatomic
variant, there is a role for TH2-mediated bile duct injury in
murine BA. Stat1 knockout mice, which generate only TH2
cytokines and are unable to make TH1 cytokines, develop a
cystic biliary form of BA after RRV infection. The role of IL-
13, an effector cytokine found to be important in TH2-
mediated diseases, was also analyzed. Stat1/IL-13 double
knockout mice showed some protection from bile duct
obstruction with improved survival, and it was concluded
that IL-13 and TH2 responses contribute to the pathogen-
esis of cystic BA.28TH17 Cellular Immunity
IL-17 has been implicated as a major pathogenic cyto-
kine contributing to autoimmune-mediated diseases. Neo-
nates have an enhanced ability to mount proinﬂammatory
TH17 responses, based on research showing that TLR-
stimulated cord blood cells produce high levels of IL-6
and IL-23, necessary cytokines for TH17 differentiation.
29
In addition, cultured cord blood CD4þ T cells can generate
signiﬁcant amounts of IL-17.30 In the neonatal setting of a
fully mature TH17 pathway, is it possible that an aggressive,
persistent TH17 response plays a role in bile duct damage in
BA? A recent study in BA found that serum IL-17a and IL-23
levels were increased in BA patients compared with healthy
age-matched controls.31 In addition, the ratio of TH17 cells/
regulatory T cells (Tregs) was signiﬁcantly higher in the
peripheral blood of BA patients. BA liver tissue had
increased mRNA expression of ROR-gt (IL-17 transcription
factor), IL-17a, IL-1b, IL-6, and transforming growth factor
b1, an increased number of IL-17a inﬁltrating cells, and a
decreased ratio of Treg/CD4þ T cells. This study implies
that TH17 inﬂammatory pathways dominate and overcome
the regulatory T-cell response, contributing to biliary injury
in BA. TH17 cell-mediated immunity requires further
investigation to determine the signiﬁcance of IL-17 to BA
pathogenesis.Regulatory T Cells
The Treg subset of CD4þ T cells is responsible for con-
trolling immune responses to prevent “bystander damage”
of healthy tissue and to prevent activation of autoreactive T
cells. The Treg subset expresses the cell surface marker
CD25high and the transcription factor forkhead box P3
(Foxp3).32 Tregs inhibit cells involved in adaptive immunity
(T- and B-cell responses) and innate immunity (macro-
phages, dendritic cells, and natural killer cells).33,34 In hu-
man neonates, the percentage of Tregs in peripheral blood
increases signiﬁcantly in the ﬁrst 5 days of life, reaching
adult levels at that time.35 Recent studies suggest that there
is a signiﬁcantly greater number of Tregs in cord blood
compared with adult Tregs.36 Furthermore, cord blood
Tregs are highly functional and can suppress T-cell prolif-
eration and TH1 IFN-g production, similar to adult Treg
function.37
In neonatal mice, Tregs exit the thymus and travel to the
spleen and lymph nodes on day 3 of life.32,33,38 Thymectomy
in 3-day-old neonatal mice results in a spectrum of organ-
speciﬁc autoimmunity that can be prevented by reconsti-
tution of the thymectomized animals early in life with
normal adult Tregs.38–40 Autoimmune disease may also
develop when exogenous insults, such as virus infection,
disrupt the maturation or functioning of Tregs. Morse et al41
showed that murine T lymphotropic virus infection on day 1
of life (but not on day 7 or 28) led to decreased release of
Tregs from the thymus and the development of autoimmune
gastritis. Kobayashi et al42 found that the administration of a
poly I:C virus mimic into neonatal thymectomized mice
resulted in worsening incidence and severity of autoim-
mune gastritis and was associated with a signiﬁcant
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reveal that neonatal viral infection can induce or exacerbate
the propensity for autoimmunity due to Treg deﬁciencies,
which sets the stage to study this mechanism of autoim-
munity in the pathogenesis of BA.
In murine BA, RRV infection must take place in the ﬁrst
48 hours of life to induce biliary disease, and the incidence
of disease is highest when virus is administered in the ﬁrst
24 hours of life.43 The necessity of early age at the time of
viral infection to generate disease leads to the question of
whether this neonatal virus infection could alter the release
of Tregs from the thymus or decrease their suppressive
capacity in the periphery, thus allowing for pathogenic
autoreactive T cells and inﬂammation to ﬂourish, stimu-
lating effector cell functions (Figure 1). Miethke et al44
characterized the frequency of Tregs in neonatal mice and
found that the liver and spleen of 3-day-old mice hadFigure 1. Hypothetical model of the role of Treg deﬁcits in
predisposed individual may (1) alter the release of Tregs from
periphery, allowing for autoreactive CD4þ T-effector cells (Teffs
cells (CTLs), and autoantibody-producing B cells, leading to prsigniﬁcantly fewer Tregs compared with 7-day-old mice,
similar to previous studies showing that Tregs begin
migration to the periphery on day 3 of life. The Treg deﬁcit
in week 1 was associated with enhanced dendritic cell
activation of natural killer (NK) cells, resulting in biliary
injury and obstruction. Lages et al45 showed that adoptive
transfer of total CD4þ T cells, but not Treg-depleted CD4þ T
cells, into RRV-infected mice was associated with increased
survival and diminished CD8þ T-cell cytotoxicity. Tucker
et al46 reported signiﬁcant deﬁcits in liver Treg frequencies
as well as Treg suppressive function in BA mice. In addition,
adoptive transfer of highly puriﬁed adult Tregs into RRV-
infected BA mice prevented the development of biliary
obstruction, dramatically increased survival and inhibited
TH1 cell-mediated biliary injury. These complimentary
studies demonstrate that Treg frequency and function are
diminished in BA; further analysis of the mechanismsBA pathogenesis. Neonatal virus infection in the genetically
the thymus or (2) decrease their regulatory capacity in the
) to ﬂourish and (3) activate macrophages, cytotoxic CD8þ T
ogressive bile duct epithelial injury.
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therapies aimed at enhancing Treg numbers and suppres-
sive capabilities in BA may lead to protection of the intra-
hepatic biliary tree from ongoing damage.Adaptive Humoral Immunity and B Cells
Humoral immune responses are initiated by interaction
of antigen with the B-cell receptor (BCR) and direct cell
contact with CD4þ T cells and/or Toll-like receptor ligands.
The BCR is composed of a membrane-bound form of IgM
(binds antigen [Ag]) and the signal transduction moiety
Ig-a/Ig-b that is necessary for activation. The engagement of
BCR by Ag leads to activation and proliferation of
Ag-speciﬁc B-cell clones that differentiate into either plas-
mablasts or germinal center B cells, which then give rise to
plasma cells or memory B cells.47 In neonatal immunity,
murine studies demonstrate that predominantly IgM anti-
body responses to T-cell–independent antigens such as plant
lectins, polysaccharides, and polymerized proteins are well
established by 2 to 3 weeks of age. In contrast, T-cell–
dependent IgG antibody responses begin atw2 weeks of age
and reach peak levels by 6 to 8 weeks of age.48–50
In humans, nearly all the IgG at birth is maternally
derived and reaches a nadir between 1.5 and 3.0 months of
age. At this point, IgG synthesis by the newborn begins; by 18
months of age, the maternally derived IgG is absent. Peak IgG
levels are not attained until 5 years of age. On the other hand,
IgM levels rise rapidly during the ﬁrst months of life,
attaining 75% of adult levels by 1 year of age. Pertinent to
the potential pathogenesis of BA is a landmark study on the
presence of IgM autoantibodies to deﬁned self molecules in
newborn humans.51 Termed “natural antibodies,” these
neonatal natural IgMs react to a selective set of self antigens,
many of which are among the target self antigens associated
with autoimmune diseases. A subset of B cells, “B-1” cells, are
in high frequency in the fetal liver and in neonates and are
the main producers of these natural antibodies.52 Evidence
exists that the IgM natural antibodies may actually inhibit
autoimmunity through facilitating clearance of apoptotic cell
debris.53,54 In contrast, it has been theorized that based on
the presence of some major disease-associated self antigens
within the IgM natural antibody repertoire, pathologic auto-
immune disease could arise through a lapse in the regulation
of otherwise benign, “natural” autoimmunity. One such cause
of this lapse in regulation could be a perinatal virus infection,
as theorized in BA.
To date, published work on humoral immunity in BA has
been limited to characterization studies, such as those
describing periductal immunoglobulin deposits.55 Over 30
years ago, Hadchouel et al56 described both IgM and IgG
immunoglobulin deposits along the basement membrane of
bile duct epithelia in the extrahepatic biliary remnant of
34% of infants with BA. Similar ductal epithelial immune
deposits have been reported in the mouse model of BA.24,27
The target antigen(s) that these immunoglobulins are
complexing with is unknown and could include self-bile
duct epithelia proteins or viral proteins present within
infected epithelia.Liu et al57 performed immunoblot analysis of sera from
BA mice and discovered autoantibodies reactive to cytosolic
proteins within bile duct epithelia. One such protein was
identiﬁed as a-enolase, and signiﬁcant elevations of
a-enolase autoantibodies were uniquely present in BA
mouse sera. One possible theory to explain the increase in
production of autoantibodies in the setting of previous virus
infection is that there is molecular mimicry between virus
and self proteins. In this study, a high degree of sequence
homology between enolase and rotavirus proteins VP4 and
VP8 were identiﬁed, and the anti-enolase antibodies bound
to both enolase and rotavirus, suggesting molecular mimicry
as a mechanism of the autoimmune response. In addition,
high levels of IgM and IgG a-enolase autoantibodies were
detected in w40% of infants and children with BA.57
Interestingly, anti-enolase antibodies have been found in
other autoimmune diseases including autoimmune liver
diseases, suggesting that this antibody may be a nonspeciﬁc
marker of autoimmunity.58,59 Future research centered on
identifying potentially pathogenic, bile-duct speciﬁc auto-
antibodies should be pursued.
B cells are not only responsible for production of anti-
bodies, but also play a key role as professional antigen-
presenting cells (APCs), with subsequent T-cell activation.
Naive neonatal APCs have limited ability to activate T cells
due to low levels of major histocompatibility complex class
II and costimulatory molecules.60 However, neonatal mice
exposed to low levels of replicating virus display increased
antigen-presentation capabilities, with subsequent TH1 cell
activation and cytotoxic T-cell function.61 Perhaps a similar
virus-induced APC activation is occurring in the neonate
with BA. To assess the importance of B cells in BA
pathogenesis, Feldman et al62 used mice deﬁcient in Ig-a
(Ig-a/) that have loss of BCR expression and function,
resulting in defective B-cell antigen presentation and
immunoglobulin production. RRV-infected Ig-a/ mice had
dramatically increased survival and lack of bile duct
obstruction. Signiﬁcantly decreased numbers of liver CD4þ
T cells, NK T cells, and NK cells and macrophages were
observed in RRV-infected Ig-a/ mice compared with
wild-type mice. Similar to other B-cell depletion stud-
ies,63–66 the RRV-infected Ig-a/ mice had increased levels
of Tregs, suggesting a link between B-cell activation and
Treg inhibition. In addition, lack of T-cell activation in RRV-
infected Ig-a/ mice was demonstrated based on markedly
decreased production of IFN-g and TNF-a from CD4þ T cells
and IFN-g from CD8þ T cells. This implies that without
B-cell antigen presentation, the T cells are not activated,
which suggests a possible mechanism of protection from
disease. B cells appear to play a critical role in the RRV-
induced mouse model of BA, and future studies aimed at
deciphering the speciﬁc role of antigen presentation and
production of pathogenic autoantibodies are necessary to
understand the impact of B cells in disease pathogenesis.Summary
Biliary atresia is a devastating disease wherein the vast
majority of patients require liver transplantation for
272 Cara L. Mack Cellular and Molecular Gastroenterology and Hepatology Vol. 1, No. 3survival. It is critical to grasp the immunopathogenesis of
BA in order to provide future therapies that control the
intrahepatic biliary inﬂammation and prevent subsequent
ﬁbrosis. Evidence exists for a key role of both arms of the
adaptive immune response in bile duct injury. The neonatal
presentation of BA provides a clue to disease pathogenesis.
Early events that impact the neonatal immune system (ie,
perinatal virus infection) may alter the immune response
and promote a progressive inﬂammatory or biliary auto-
immune disease. To advance our understanding of the eti-
ology of BA, future studies should focus on those unique
aspects of the neonatal immune system that have gone
awry, as detailed throughout this review.References
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